DITROPAN XL
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
DITROPAN XL by Johnson & Johnson is clinical pharmacology oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Approved for overactive bladder with symptoms of urge urinary incontinence, urgency, frequency and 2 more indications. First approved in 1998.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DITROPAN XL is an extended-release oral tablet containing oxybutynin chloride, an anticholinergic antispasmodic agent. It treats overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults and children aged 6+ with neurogenic detrusor overactivity. The drug works by inhibiting muscarinic acetylcholine receptors on bladder smooth muscle, increasing bladder capacity and reducing involuntary contractions.
$0.042BPart D
LOE ApproachingDeclining
Mature product in decline phase with modest Medicare utilization signals shrinking brand team investment and focus on generic transition management.
Mechanism of Action
CLINICAL PHARMACOLOGY Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to…
Worked on DITROPAN XL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.